
# 5 Year Summary of FDA Drug 483s 2015-2019



## Jeanne Moldenhauer

www.pda.org/bookstore

# 5 Year Summary of FDA Drug 483s

Jeanne Moldenhauer

PDA
Bethesda, MD, USA
DHI Publishing, LLC
River Grove, IL, USA

#### 10 9 8 7 6 5 4 3 2 1

ISBN: 978-1-942911-43-2

Copyright © 2020 Jeanne Moldenhauer

All rights reserved.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The author has made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the author to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the author and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



Connecting People, Science and Regulation®



**PDA Global Headquarters** 

Bethesda Towers, Suite 150 4350 East-West Highway Bethesda, MD 20814 United States www.pda.org/bookstore 001-301-986-0293 Davis Healthcare International Publishing, LLC

2636 West Street River Grove IL 60171 United States www.DHIBooks.com

## **CONTENTS**

1	Introduction	
	What is included in a FDA 483?	I
	How Does a FDA 483 Compare to a Warning Letter?	2
	Responding to a FDA 483	2 2 2
	During the inspection	2
	The actual company response to the FDA regarding the FDA 483	3
	Following the Response	3
	Why Review FDA 483s?	4
	Literature Cited	4
2	Summary of Drug FDA Observations	5
	Background	5
	Tables of Five Year Data Summaries can be found on the following pages:	
	21 CFR 211.22	6
	21 CFR 211.25	7
	21 CFR 211.28	9
	21 CFR 211.34	9
	21 CFR 211.42	9
	21 CFR 211.44	12
	21 CFR 211.46	13
	21 CFR 211.48	13
	21 CFR 211.50	14
	21 CFR 211.52	14
	21 CFR 211.56	14
	21 CFR 211.65	15
	21 CFR 211.67	15
	21 CFR 211.68	18
	21 CFR 211.80	19
	21 CFR 211.82	20
	21 CFR 211.84	21

### Table of Contents

21 CFR 211.86	26
21 CFR 211.87	26
21 CFR 211.89	26
21 CFR 211.94	27
21 CFR 211.100	27
21 CFR 211.101	28
21 CFR 211.103	30
21 CFR 211.105	30
21 CFR 211.110	31
21 CFR 211.111	33
21 CFR 211.113	33
21 CFR 211.115	34
21 CFR 211.122	34
21 CFR 211.125	36
21 CFR 211.130	37
21 CFR 211.132	38
21 CFR 211.134	39
21 CFR 211.137	40
21 CFR 211.142	40
21 CFR 211.150	41
21 CFR 211.160	41
21 CFR 211.165	47
21 CFR 211.166	48
21 CFR 211.167	50
21 CFR 211.170	51
21 CFR 211.176	53
21 CFR 211.180	54
21 CFR 211.182	57
21 CFR 211.184	58
21 CFR 211.186	59
21 CFR 211.188	61
21 CFR 211.192	66
21 CFR 211.194	67
21 CFR 211.196	72
21 CFR 211.198	72
21 CFR 211.204	76
21 CFR 211.208	77
21 CFR 212.10	78
21 CFR 212.20	78
21 CFR 212.30	80
21 CFR 212.40	81
21 CFR 212.50	82
21 CFR 212.60	84
21 CFR 212.60 21 CFR 212.61	
	86
21 CFR 212.70	86
21 CFR 212.71	89

Background What are the Most Frequently Occurring Observations? Conclusion Literature Cited  Available Resources	10     11   13   13
What are the Most Frequently Occurring Observations? Conclusion	    3
What are the Most Frequently Occurring Observations?	111
What are the Most Frequently Occurring Observations?	
Background	110
_	
Analysis of Drug FDA 483 Summary	110
Literature Cited	109
FDCA 760	108
FDCA 505-1	106
FDCA 503B	106
FDCA 501	101
21 CFR 314.80	100
	100
	97
	96
	96
	90 95
	90
21 CFR 212.100	90
21 CFR 212.80	89
	21 CFR 212.100 21 CFR 310.305 21 CFR 314.80 21 CFR 314.81 21 CFR 329.100 21 CFR 361.1 21 CFR 94 21 CFR 314.80 FDCA 501 FDCA 503B FDCA 505-1 FDCA 760  Literature Cited